2026Q1医药业绩前瞻：华创医药投资观点&研究专题周周谈·第168期

Investment Rating - The report maintains a "Strong Buy" rating for several companies in the innovative drug sector, particularly highlighting the growth potential of companies like 加科思 (JAK-23E73) and others in the medical device and life sciences service sectors [10][15][17]. Core Insights - The innovative drug sector in China is experiencing high-quality growth, significantly outpacing global averages, with a focus on domestic companies gaining international market share [10]. - The medical device industry is seeing a recovery in bidding scales and a shift towards innovation, with companies like 迈瑞医疗 and 澳华内镜 being recommended for investment [15]. - The life sciences service sector is expected to rebound as demand increases, driven by both domestic and international markets, with companies like 百普赛斯 and 药康生物 highlighted for their growth potential [17]. Summary by Sections Market Review - The medical index increased by 1.49%, outperforming the沪深300 index by 2.9 percentage points, ranking 5th among 30 sectors [7]. - Top-performing stocks included 美诺华 and 万邦德, while stocks like 科源制药 and 长药退 faced significant declines [6][30]. Innovative Drugs - China has become a key player in global innovative drug development, with a notable increase in overseas licensing deals, suggesting a shift towards an "innovation-driven" revenue era [10]. - Recommended companies include 百利天恒, 百济神州, and 恒瑞医药, among others [10]. Medical Devices - The high-value consumables sector is seeing easing pressure from centralized procurement, with companies like 春立医疗 and 迈普医学 recommended for their growth potential [15]. - The medical equipment sector is expected to experience a recovery, with significant growth anticipated in 2025 [15]. Life Sciences Services - The sector is poised for a rebound, with increasing demand from both domestic and international markets, and companies like 百普赛斯 and 药康生物 are expected to benefit [17]. Traditional Chinese Medicine - The report emphasizes the importance of basic drugs and state-owned enterprise reforms, recommending companies like 昆药集团 and 康缘药业 for their growth potential [21]. Pharmacy Sector - The pharmacy sector is expected to benefit from the acceleration of prescription outflow and an improved competitive landscape, with companies like 老百姓 and 益丰药房 highlighted for investment [18]. Medical Services - The report suggests a positive outlook for private medical services, particularly for companies like 固生堂 and 爱尔眼科, due to market improvements and expanding insurance coverage [20].